Drug Profile

Recombinant anti-LAG-3 humanised monoclonal antibody - Shanghai Fosun Pharmaceutical

Latest Information Update: 20 Apr 2022

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Shanghai Fosun Pharmaceutical
Class Antineoplastics; Immunotherapies; Monoclonal antibodies
Mechanism of Action Antibody-dependent cell cytotoxicity; CD223 antigen inhibitors; T lymphocyte stimulants

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

20 Apr 2022 Preclinical trials in Lymphoma in China (Parenteral) (Shanghai Fosun Pharmaceutical pipeline, April 2022)
20 Apr 2022 Preclinical trials in Solid tumours in China (Parenteral) (Shanghai Fosun Pharmaceutical pipeline, April 2022)
20 Apr 2022 The National Medical Products Administration approves IND application for Recombinant anti-LAG3 humanised monoclonal antibody in Solid tumours and Lymphoma (Shanghai Fosun Pharmaceutical pipeline, April 2022)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com